DARATUMUMAB (DARZALEX®)

DRUG2 trials

Sponsors

Hospices Civils de Lyon, University Hospital, Martin

Conditions

Cutaneous Adverse Drug Reactions (CADR)ImmunotherapyMicrovascular Inflammation - MVI in Kindey Transplant RecipientsToxic Epidermal Necrolysis

Phase 1

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Not yet recruitingNCT07110662

Hospices Civils de LyonCutaneous Adverse Drug Reactions (CADR), Immunotherapy, Toxic Epidermal Necrolysis

Start: 2025-10-29End: 2029-04-29Target: 9Updated: 2025-08-07

Phase 4

DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)

Active, not recruitingNCT07274462

University Hospital, MartinMicrovascular Inflammation - MVI in Kindey Transplant Recipients

Start: 2025-11-01End: 2027-09-30Target: 20Updated: 2025-12-10